64x Bio, a biotechnology company focused on scalable solutions for advanced therapy production, has officially launched AAV Apex Suite, a high-performance product line aimed at solving one of gene therapy’s most pressing issues: manufacturing constraints. The launch follows the formation of strategic collaborations with five leading global biopharma and CDMO partners, underscoring industry demand for improved viral vector production.

Gene therapies hold transformative potential, but their reach has been limited by high manufacturing costs and low scalability. AAV Apex Suite tackles this challenge head-on, offering suspension-adapted HEK293 cell lines optimized for transient transfection and delivering titers exceeding E15 vg/L. These results have been independently validated across various serotypes and therapeutic payloads, consistently achieving high yield and quality.

"The grand challenges for gene therapies have shifted from target organ specificity and how to fit large genes into small capsids to the challenge of low-cost, high-quality manufacturing of AAV therapies. So it is with great pleasure that we see this milestone from 64x," said George Church, PhD, Co-founder of 64x Bio.

The AAV Apex Suite is powered by 64x Bio’s VectorSelect platform, an advanced system that maps the cellular pathways driving productivity. VectorSelect combines genetic and metabolic profiling to guide both cell line engineering and media formulation. As the platform’s dataset continues to grow, 64x Bio is applying computational tools to refine and accelerate new product development.

“Our goal is to enable gene therapies and next generation medicines to succeed by fixing the cost and scale problems that hold them back,” said Lexi Rovner, PhD, CEO and Co-founder of 64x Bio. “Our team has done incredible work to develop AAV Apex Suite as an initial demonstration of what our platform can achieve. We’re already building on this foundation and continuing to develop more that we’ll be sharing soon,” she added.

The launch of AAV Apex Suite comes at a critical time for gene therapy manufacturing. Five prominent biopharma and CDMO partners have already committed to collaborations, highlighting the urgency to resolve production limitations. While AAV Apex Suite currently supports transient production, 64x Bio is actively developing stable cell lines, with plans to expand the suite further.

Beyond the off-the-shelf capabilities of AAV Apex Suite, the company is also offering custom solutions through its VectorSelect platform. These custom projects extend beyond AAV, as 64x Bio continues to explore applications in broader advanced biologics manufacturing.

To learn more about AAV Apex Suite or discuss partnership opportunities, visit www.64xbio.com.

‍